Patient‐reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy
- 3 June 2020
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 147 (11) , 3085-3089
Abstract
There has been minimal research on the prognostic value of patient‐reported outcomes (PROs) for immune checkpoint inhibitors (ICIs). The relative performance of PROs compared to established markers such as Eastern Cooperative Oncology Group Performance Status (ECOG‐PS) and the Lung Immune Prognostic Index (LIPI) is unknown. In our study, data from the advanced nonsmall cell lung cancer (NSCLC) single‐arm atezolizumab trials BIRCH, FIR and randomised‐trials OAK, POPLAR (atezolizumab vs docetaxel) were pooled. The study included 1548 participants who initiated atezolizumab. The associations between pretreatment PROs and overall survival (OS) and progression‐free survival (PFS) were modelled using Cox proportional hazards regression. Prediction performance was assessed using the C‐statistic (c). PROs were recorded via the EORTC QLQ‐C30 and QLQ‐LC13. Patient‐reported physical function, fatigue, global health, appetite, role function, pain, dyspnoea, social function, constipation, nausea‐vomiting, emotional function and coughing were significantly associated with OS and PFS on univariable and adjusted analysis (P < .05). Physical function (c = 0.654), fatigue (c = 0.653) and global health (c = 0.650) were the most predictive variables for OS. Comparatively, the OS prediction performance of physical function (c = 0.65) was superior to ECOG‐PS (c = .59) and LIPI (c = 0.63). On multivariable analysis physical function, ECOG‐PS and LIPI were all significant (P < .001). In conclusion, PROs were identified as independent prognostic factors for OS and PFS in advanced NSCLC patients receiving ICI therapy. Further, patient‐reported physical function was more predictive of OS than ECOG‐PS and LIPI and contained independent information. This highlights the value of PROs as prognostic and stratification factors for clinical use and research trials of ICIs.Keywords
Funding Information
- Cancer Council South Australia
This publication has 15 references indexed in Scilit:
- Prognostic Significance of Patient-Reported Outcomes in CancerJCO Oncology Practice, 2020
- Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic reviewThe Lancet Oncology, 2019
- Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung CancerJAMA Oncology, 2019
- Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsJournal of Thoracic Oncology, 2019
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markersBritish Journal of Cancer, 2017
- Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer TreatmentJAMA, 2017
- The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancerQuality of Life Research, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- What Is the Value of the Routine Use of Patient-Reported Outcome Measures Toward Improvement of Patient Outcomes, Processes of Care, and Health Service Outcomes in Cancer Care? A Systematic Review of Controlled TrialsJournal of Clinical Oncology, 2014